This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

Lorence Kim Biography and Net Worth

CFO of Moderna

Lorence Kim joined TRV as a venture partner in 2020. He was previously the Chief Financial Officer of Moderna, guiding $4.4 billion of capital raising to support the company’s platform efforts in mRNA medicines and the discovery and development of a pipeline of 20+ candidates across infectious disease, oncology, rare disease and autoimmune disease. Prior to Moderna, Lorence spent 14 years at Goldman Sachs, where his last role was the co-head of the US biotech banking practice. Lorence is a member of the Board of Governors of the American Red Cross, and previously served on the board of directors of Seres Therapeutics. Lorence lives with his wife and three children in New York City.

What is Lorence H. Kim's net worth?: The estimated net worth of Lorence H. Kim is at least $6.59 million as of July 22nd, 2022. Dr. Kim owns 60,500 shares of Moderna stock worth more than $6,585,425 as of April 24th. This net worth evaluation does not reflect any other assets that Dr. Kim may own. Learn More about Lorence H. Kim's net worth.
How do I contact Lorence H. Kim?: The corporate mailing address for Dr. Kim and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at (617) 714-6500 and via email at [email protected]. Learn More on Lorence H. Kim's contact information.
Has Lorence H. Kim been buying or selling shares of Moderna?: Lorence H. Kim has not been actively trading shares of Moderna during the past quarter. Most recently, Lorence H. Kim sold 241,000 shares of the business's stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $58.30, for a transaction totalling $14,050,300.00. Following the completion of the sale, the chief financial officer now directly owns 1,280,819 shares of the company's stock, valued at $74,671,747.70. Learn More on Lorence H. Kim's trading history.
Who are Moderna's active insiders?: Moderna's insider roster includes Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), W. Cornwell (Director), Arpa Garay (Insider), Lori Henderson (General Counsel), Lori Henderson (General Counsel), Stephen Hoge (President), Lorence Kim (CFO), Shannon Klinger (Insider), David Meline (CFO), Jamey Mock (CFO), Elizabeth Nabel (Director), Paul Sagan (Director), and Tal Zaks (Insider). Learn More on Moderna's active insiders.
Are insiders buying or selling shares of Moderna?: During the last year, insiders at the sold shares 58 times. They sold a total of 830,770 shares worth more than $95,409,532.71. The most recent insider tranaction occured on April, 17th when Director Noubar Afeyan sold 15,000 shares worth more than $1,550,700.00. Insiders at Moderna own 15.2% of the company. Learn More about insider trades at Moderna.
Information on this page was last updated on 4/17/2024.

Lorence H. Kim Insider Trading History at Moderna

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/2/2020	Sell	241,000	$58.30	$14,050,300.00	1,280,819
5/27/2020	Sell	241,000	$51.13	$12,322,330.00	1,424,875
5/12/2020	Sell	241,000	$64.49	$15,542,090.00	1,234,153
4/15/2020	Sell	20,000	$36.21	$724,200.00	1,236,333
3/16/2020	Sell	20,000	$26.19	$523,800.00	1,259,718
2/25/2020	Sell	1,348	$25.63	$34,549.24	1,301,262
2/7/2020	Sell	33,295	$23.06	$767,782.70	1,302,510
1/27/2020	Sell	23,805	$23.01	$547,753.05	1,336,705
1/22/2020	Sell	2,000	$23.04	$46,080.00	1,360,510
12/6/2019	Sell	238,532	$20.00	$4,770,640.00	1,371,684

Lorence H. Kim Buying and Selling Activity at Moderna

Moderna Company Overview

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $103.74

$103.56

$108.23

50 Day Range

MA: $101.85

$86.99

$111.98

2 Week Range

Now: $103.74

$62.55

$142.79

Volume

942,452 shs

Average Volume

4,076,220 shs

Market Capitalization

$39.72 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.62